Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats
- PMID: 19128473
- PMCID: PMC2628672
- DOI: 10.1186/1472-6807-9-1
Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats
Abstract
Background: Mesothelin is a 40 kDa protein present on the surface of normal mesothelial cells and overexpressed in many human tumours, including mesothelioma and ovarian and pancreatic adenocarcinoma. It forms a strong and specific complex with MUC16, which is also highly expressed on the surface of mesothelioma and ovarian cancer cells. This binding has been suggested to be the basis of ovarian cancer metastasis. Knowledge of the structure of this protein will be useful, for example, in building a structural model of the MUC16-mesothelin complex. Mesothelin is produced as a precursor, which is cleaved by furin to produce the N-terminal half, which is called the megakaryocyte potentiating factor (MPF), and the C-terminal half, which is mesothelin. Little is known about the function of mesothelin and there is no information on its possible three-dimensional structure. Mesothelin has been reported to be homologous to the deafness-related inner ear proteins otoancorin and stereocilin, for neither of which the three-dimensional structure is known.
Results: The BLAST and PSI-BLAST searches confirmed that mesothelin and mesothelin precursor proteins are remotely homologous to stereocilin and otoancorin and more closely homologous to the hypothetical protein MPFL (MPF-like). Secondary structure prediction servers predicted a predominantly helical structure for both mesothelin and mesothelin precursor proteins and also for stereocilin and otoancorin. Three-dimensional structure prediction servers INHUB and I-TASSER produced structural models for mesothelin, which consisted of superhelical structures with ARM-type repeats in conformity with the secondary structure predictions. Similar ARM-type superhelical repeat structures were predicted by 3D-PSSM server for mesothelin precursor and for stereocilin and otoancorin proteins.
Conclusion: The mesothelin superfamily of proteins, which includes mesothelin, mesothelin precursor, megakaryocyte potentiating factor, MPFL, stereocilin and otoancorin, are predicted to have superhelical structures with ARM-type repeats. We suggest that all of these function as superhelical lectins to bind the carbohydrate moieties of extracellular glycoproteins.
Figures




Similar articles
-
Otoancorin, an inner ear protein restricted to the interface between the apical surface of sensory epithelia and their overlying acellular gels, is defective in autosomal recessive deafness DFNB22.Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6240-5. doi: 10.1073/pnas.082515999. Epub 2002 Apr 23. Proc Natl Acad Sci U S A. 2002. PMID: 11972037 Free PMC article.
-
Sequence similarity between stereocilin and otoancorin points to a unified mechanism for mechanotransduction in the mammalian inner ear.BMC Cell Biol. 2002 Nov 25;3:28. doi: 10.1186/1471-2121-3-28. Epub 2002 Nov 25. BMC Cell Biol. 2002. PMID: 12445334 Free PMC article.
-
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6. doi: 10.1073/pnas.96.20.11531. Proc Natl Acad Sci U S A. 1999. PMID: 10500211 Free PMC article.
-
Mesothelin: a new target for immunotherapy.Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42. doi: 10.1158/1078-0432.CCR-03-0801. Clin Cancer Res. 2004. PMID: 15217923 Review.
-
Clinical impacts of mesothelin expression in gastrointestinal carcinomas.World J Gastrointest Pathophysiol. 2016 May 15;7(2):218-22. doi: 10.4291/wjgp.v7.i2.218. World J Gastrointest Pathophysiol. 2016. PMID: 27190694 Free PMC article. Review.
Cited by
-
RNAseq profiling of blood from patients with coronary artery disease: Signature of a T cell imbalance.J Mol Cell Cardiol Plus. 2023 Jun;4:100033. doi: 10.1016/j.jmccpl.2023.100033. Epub 2023 Mar 25. J Mol Cell Cardiol Plus. 2023. PMID: 37303712 Free PMC article.
-
The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment.Cancers (Basel). 2018 Aug 21;10(9):277. doi: 10.3390/cancers10090277. Cancers (Basel). 2018. PMID: 30134520 Free PMC article. Review.
-
Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases.Mol Cancer Res. 2020 Feb;18(2):229-239. doi: 10.1158/1541-7786.MCR-19-0688. Epub 2019 Nov 1. Mol Cancer Res. 2020. PMID: 31676721 Free PMC article.
-
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.Int J Mol Sci. 2020 Jun 6;21(11):4067. doi: 10.3390/ijms21114067. Int J Mol Sci. 2020. PMID: 32517181 Free PMC article. Review.
-
Mesothelin: An Immunotherapeutic Target beyond Solid Tumors.Cancers (Basel). 2022 Mar 18;14(6):1550. doi: 10.3390/cancers14061550. Cancers (Basel). 2022. PMID: 35326701 Free PMC article. Review.
References
-
- Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994;269:805–808. - PubMed
-
- Yamaguchi N, Yamamura Y, Konishi E, Ueda K, Kojima T, Hattori K, Oheda M, Imai N, Taniguchi Y, Tamura M, et al. Characterization, molecular cloning and expression of megakaryocyte potentiating factor. Stem Cells. 1996;14:62–74. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous